Eli Lilly (NYSE: LLY) is ramping up its investments in drug development, particularly in the weight-loss sector, while also expanding its pipeline through acquisitions. The company recently announced a $7 billion deal to acquire Kelonia Therapeutics, which is developing a CAR-T gene therapy for cancer currently in phase 1 trials. This strategic move diversifies Lilly’s offerings beyond weight-loss drugs, an area facing increasing competition.
The healthcare sector is experiencing notable growth, with health spending projected to rise by 7.2% from 2023 to 2024, outpacing previous years. Eli Lilly’s recent financial performance reflects this trend, reporting a 43% year-over-year revenue increase and a 51% jump in earnings per share for the fourth quarter. Despite a forward P/E ratio of 40, which is below its five-year average, the stock remains attractive given its robust growth potential.
For market professionals, Eli Lilly presents an intriguing opportunity, particularly as it seeks to balance its weight-loss drug portfolio with promising cancer therapies. However, investors may want to consider alternative stocks identified by analysts that could offer higher returns.
Source: nasdaq.com